The Future of Pharma Across All Sectors in the Artificial Intelligence Era

Miltiadis D. Lytras is a Professor of Artificial Intelligence, Digital Transformation, and Knowledge Management at Effat University (Saudi Arabia) and The American College of Greece. He is an internationally recognized researcher with extensive experience in AI, data science, smart systems, and digital innovation across healthcare, education, government, and business. He has served as Principal Investigator and Senior Researcher in numerous international and national research projects and has published more than 100 peer-reviewed articles and over 40 books with leading international publishers. His work focuses on responsible and human-centered AI, advanced decision-making systems, and the strategic impact of emerging technologies on organizations and society. Ahmed is an experienced professional with almost 2 decades of expertise in pharmaceutical, academia, and healthcare industries. He has strong leadership skills, excellent communication abilities, and an entrepreneurial spirit. He specializes in clinical trials and has a proven track record of designing and running international, multicentre clinical trial projects. He is a thought leader in R&D ecosystem transformation and the use of technology to advance health. He also has a strong network of investigators and key opinion leaders, both locally and globally, and is actively involved in various initiatives to unlock the clinical trials ecosystem. Ahmed is passionate about enabling others to conduct more clinical trials with the ultimate aim of improving the health of millions of people around the world. Patricia de Pablos is a Professor of Business Administration at the University of Oviedo in Spain. Her field of research focuses on knowledge management, healthcare sector, innovation, information technologies and technological disruption. She has contributed to numerous academic publications. She has wide editorial experience in journals, books and book series. She serves as Editor in Chief of International Journal of Asian Business and Information and Journal of Science and Technology Policy Management. Paraskevi Papadopoulou is Professor of Biology in the Biomedical Sciences and Environmental Studies Programs, Department of Natural Sciences, School of Science and Technology at Deree-The American College of Greece, Athens, Greece. Her research activity covers a wide range of subject areas with a main focus in the fields of structural biology/molecular biophysics and bioinformatics and on structural and self-assembly studies of fibrous proteins. Her current research engagement expands on environmental health issues, big data analytics in bioinformatics, medicine, health and healthcare, the evolution of consciousness plus on Mediterranean biodiversity and green roofs, and innovative teaching and learning methods in STEM disciplines. https://acg150.acg.edu/persons/paraskevi-papadopoulou-phd/ Dr Sofia Konstantinopoulou, MD, FAAP, is a triple US board-certified pediatric pulmonologist and sleep medicine physician. She completed her training and gained extensive experience at the Children’s Hospital of Philadelphia, where she also held an academic position as Assistant Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania.Currently, Dr Konstantinopoulou serves as an attending physician specializing in pediatric pulmonology and sleep medicine at Sheikh Khalifa Medical City (SEHA), the premier referral center for pediatrics in the country. In this role, she manages some of the most challenging cases in pediatric respiratory and sleep medicine, collaborating closely with multidisciplinary teams to deliver compassionate, family-centered care. She also holds the position of clinical lead for the Aerodigestive Program at her institution.With a primary focus on patients with sleep-disordered breathing requiring home mechanical ventilation, Dr Konstantinopoulou is dedicated to providing high-quality care and improving outcomes for these individuals. She plays a pivotal role in medical education as core faculty for her institution's ACGME-accredited pediatric residency program and the World Sleep Academy (WSA).Additionally, Dr Konstantinopoulou is actively involved in professional organizations such as CHEST, the American Academy of Sleep Medicine (AASM), and the American Thoracic Society (ATS), where she contributes her expertise as a member of the International Health Committee.Passionate about collaboration and advancing clinical research, health advocacy, and medical education, Dr Konstantinopoulou welcomes opportunities to work with partners worldwide on impactful projects in her field.Dr. Alajlan is a Dialysis clinical pharmacist and researcher. She has bachelor degree in Doctor of Pharmacy (PharmD) she is member of multiple international and national pharmacy associations. Dr. Alajlan received national and international awards in research project and has multiple publications in the field of social and behaviors, pharmacy, and education.

• 1. Introduction: Navigating the Complex Landscape of Pharma2. Disrupting Technologies for Future Pharma: From Analytics to Super Intelligence3. The role of AI-enabled analytics in healthcare4. Artificial Intelligence in the Pharmaceutical Industry: Applications, Challenges, and Future Directions5. Trends Shaping the Future of the Pharmaceutical Industry6. AI-Driven Pharma Strategy and Operating Models: From Digital Adoption to Intelligent Transformation7. Generic Drugs and Biosimilars: Opportunities for Access and Affordability8. Over-the-Counter Medications: Meeting Consumer Needs in the Digital Age9. Medical Devices and Diagnostics: Enhancing Patient Care and Outcomes10. Global Health Challenges and Access to Medicines11. Precision Medicine: Personalising Treatments for Improved Outcomes12. Future Outlook: Anticipating Trends and Opportunities13. The Role of Artificial Intelligence in Transforming Clinical Research and Evidence Generation14. Artificial Intelligence in Clinical Trials: A Transformative Force15. The Role of Learning and Development in AI-Transformed Pharma Industry.16. Pharma Industry 2040: A catalyst for resilient change